Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 3,81 MB, PDF-dokument
Originalsprog | Engelsk |
---|---|
Artikelnummer | 101013 |
Tidsskrift | Cell Reports Medicine |
Vol/bind | 4 |
Udgave nummer | 4 |
Antal sider | 11 |
ISSN | 2666-3791 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
The authors thank Anirban Maitra and David Ting for their advice and guidance. Figures 1A, 1B, and 2A were created with BioRender.com. The study was funded by Valar Labs, Inc., V.N. Viswesh Krishna, A.J. D.V. P.R. and E.A.C. were involved in developing the study, and Viswesh Krishna and P.R. were involved in supervising the study. Vrishab Krishna and E.T. processed the images. Viswesh Krishna and Vrishab Krishna developed the model and ran the statistical tests. Vrishab Krishna and V.N. produced the figures. V.N. and Viswesh Krishna drafted the manuscript. K.S. and A.S. were involved in acquisition of the UPMC samples, and J.S.J. was involved in the acquisition of the Copenhagen samples. All authors critically edited the manuscript. Viswesh Krishna, A.J. D.V. and P.R. are founders of Valar Labs, Inc. and may own stocks. V.N. Vrishab Krishna, E.T. and H.B. are employees of Valar Labs, Inc. E.A.C. D.S. and A.H. are advisors to Valar Labs, Inc.
Funding Information:
The authors thank Anirban Maitra and David Ting for their advice and guidance. Figures 1 A, 1B, and 2 A were created with BioRender.com . The study was funded by Valar Labs, Inc.
Publisher Copyright:
© 2023 Valar Labs, Inc.
ID: 362891544